陽子線とIMRTとの２次がんの発生率を比べる論文の一つを見つけた。
J Radiat Res. 2017 May; 58(3): 363–371.
Published online 2016 Oct 25. doi: 10.1093/jrr/rrw088
PMCID: PMC5440886
PMID: 27789564
Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients
Masaya Tamura,1 Hideyuki Sakurai,2 Masashi Mizumoto,2 Satoshi Kamizawa,2 Shigeyuki Murayama,3 Haruo Yamashita,3 Seishin Takao,4 Ryusuke Suzuki,4 Hiroki Shirato,1,5 and Yoichi M. Itocorresponding author6
失礼だが笑いをこらえることができなかった。
タレントdaigoの中になんでも英語の略字、３文字、で笑いを取る人がいるが
それをギャグでなく真面目くさってお医者さんがやっているのが滑稽だった。
例えばこんな風だ。
proton beam therapy (PBT) in place of intensity-modulated X-ray therapy (IMXT)
lifetime attributable risk (LAR)
whole craniospinal (WCNS) irradiation
dose–volume histograms (DVHs)
Intensity-modulated X-ray therapy (IMXT)
3D radiation treatment planning system (3DTPS)
organ equivalent dose (OED)
regions of interest (ROIs)
number needed to treat (NNT)
90% confidence interval (CI)
Life Span Study (LSS)
volumetric multiple arc therapy (VMAT)
The risk equivalent dose (RED)
J Radiat Res. 2017 May; 58(3): 363–371.
Published online 2016 Oct 25. doi: 10.1093/jrr/rrw088
PMCID: PMC5440886
PMID: 27789564
Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients
Masaya Tamura,1 Hideyuki Sakurai,2 Masashi Mizumoto,2 Satoshi Kamizawa,2 Shigeyuki Murayama,3 Haruo Yamashita,3 Seishin Takao,4 Ryusuke Suzuki,4 Hiroki Shirato,1,5 and Yoichi M. Itocorresponding author6
失礼だが笑いをこらえることができなかった。
タレントdaigoの中になんでも英語の略字、３文字、で笑いを取る人がいるが
それをギャグでなく真面目くさってお医者さんがやっているのが滑稽だった。
例えばこんな風だ。
proton beam therapy (PBT) in place of intensity-modulated X-ray therapy (IMXT)
lifetime attributable risk (LAR)
whole craniospinal (WCNS) irradiation
dose–volume histograms (DVHs)
Intensity-modulated X-ray therapy (IMXT)
3D radiation treatment planning system (3DTPS)
organ equivalent dose (OED)
regions of interest (ROIs)
number needed to treat (NNT)
90% confidence interval (CI)
Life Span Study (LSS)
volumetric multiple arc therapy (VMAT)
The risk equivalent dose (RED)